BIODESIX INC (BDSX) - Dilution Analysis

S-3 filing: This filing relates to the registration for resale of up to 375,000 shares of common stock issuable upon the exercise of warrants held by a selling stockholder.

10-Q filing | 9.7M shares outstanding

10-Q filing | 7.5M shares outstanding

10-Q filing | 146.7M shares outstanding

10-Q filing | 146.5M shares outstanding

10-K filing | 146.0M shares outstanding

10-Q filing | 146.3M shares outstanding

S-3 filing: The filing is an S-3 registration statement for the resale of up to 62,202,399 shares of common stock by selling stockholders.

S-3 filing: Biodesix, Inc. files an S-3 to offer shares of common stock, preferred stock, warrants, rights to purchase common stock, preferred stock or units, as well as units that include any of these securities, up to an aggregate offering price of $250,000,000.

10-Q filing | 145.2M shares outstanding

S-1/A filing: This prospectus relates to the proposed resale or other disposition by the selling stockholders of up to 30,434,280 shares of Common Stock issuable upon the conversion of 760,857 shares of Series A Non-Voting Convertible Preferred Stock.

10-Q filing | 114.7M shares outstanding

S-1 filing: This S-1 filing relates to the proposed resale of up to 30,434,280 shares of Common Stock by selling stockholders, issuable upon the conversion of Series A Non-Voting Convertible Preferred Stock.

10-K filing | 96.9M shares outstanding

10-Q filing | 90.5M shares outstanding

10-Q filing | 78.5M shares outstanding

10-Q filing | 77.8M shares outstanding

10-K filing | 78.0M shares outstanding

8-K filing: Biodesix, Inc. closed a public offering of 35,075,000 shares of common stock at $1.15 per share, and a private placement of 278,514 shares of common stock to certain members of management at $1.15 per share, raising gross proceeds of approximately $70.7 million. ($40.66M proceeds)

10-Q filing | 40.4M shares outstanding

10-Q filing | 40.0M shares outstanding

S-3 filing: This S-3 filing relates to the proposed resale of 2,877,092 shares of common stock by selling stockholders. The company will not receive any proceeds from the sale.

10-Q filing | 39.8M shares outstanding

8-K filing: Biodesix, Inc. completed a private placement offering on April 7, 2022, selling 6,508,376 shares of common stock at $1.79 per share for approximately $11.7 million in gross proceeds. ($11.7M proceeds)

10-K filing | 31.3M shares outstanding

8-K filing: Biodesix, Inc. entered into a purchase agreement with Lincoln Park Capital Fund, LLC, for the sale of up to $50.0 million of shares of common stock, and issued 184,275 shares to Lincoln Park as a commitment fee.

8-K filing: Biodesix, Inc. completed an at-the-market offering on December 30, 2021, raising approximately $16.3 million in gross proceeds from the sale of 3,756,994 common shares. ($16.3M proceeds)

S-3/A filing: Biodesix, Inc. may offer and sell shares of common stock, preferred stock, warrants, rights to purchase common stock, preferred stock or units, as well as units that include any of these securities, with an aggregate offering price of up to $250,000,000.

S-3 filing: This is an S-3 filing for a mixed shelf offering of common stock, preferred stock, and/or rights to purchase common stock, preferred stock, or units, with an aggregate offering price of up to $250,000,000.

10-Q filing | 27.0M shares outstanding

10-Q filing | 27.0M shares outstanding

10-Q filing | 26.9M shares outstanding

10-K filing | 26.6M shares outstanding

10-Q filing | 26.5M shares outstanding

S-1/A filing: This S-1/A filing details an offering of 4,166,667 shares of common stock, with an over-allotment option of 625,000 shares, at an assumed price of $18.00 per share. The company intends to use the net proceeds for commercial expansion, product pipeline development, acquisition milestone payment, and working capital.

S-1/A filing: This is an S-1/A filing with information on voting rights, dividend rights, liquidation rights, and preemptive rights of common stock holders. It also includes covenants related to restrictions on selling or transferring common stock and securities convertible into common stock.

S-1/A filing: The document describes the terms and conditions of stock options granted under the company's equity incentive plans, including vesting schedules, payment methods, and transferability restrictions. It also discusses compliance with securities laws, tax consequences, and voting agreements related to the acquired shares. Additionally, the document includes an office lease agreement and various exhibits related to the stock option grants.

S-1 filing: This is an S-1 filing for Biodesix, Inc. which includes exhibit of a warrant to purchase Series G Preferred Stock. The exhibit also contains information about amendments to investor rights agreement.